A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Bevacizumab|DRUG: Docetaxel|DRUG: CPT-11|DRUG: Paclitaxel|DRUG: Vinorelbine Tartrate|DRUG: Gemcitabine
Sponsor: Duke University
Collaborators: Genentech, Inc.